Atea Pharmaceuticals Inc.

39.76-0.9500-2.33%Vol 391.77K1Y Perf 31.77%
Apr 22nd, 2021 16:00 DELAYED
BID39.50 ASK43.95
Open40.70 Previous Close40.71
Pre-Market- After-Market-
 - -%  - -
Target Price
74.00 
Analyst Rating
— — 0.00
Potential %
86.12 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+ —    45.35
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap3.29B 
Earnings Rating
Price Range Ratio 52W %
22.29 
Earnings Date
30th Mar 2021

Today's Price Range

39.7341.76

52W Range

24.1594.17

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-11.53%
1 Month
-42.67%
3 Months
-26.74%
6 Months
-
1 Year
31.77%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AVIR39.76-0.9500-2.33
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
Earnings HistoryEstimateReportedSurprise %
Q03 2020-1.06-1.74-64.15
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report0.25
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume391.77K
Shares Outstanding82.74M
Trades Count4.21K
Dollar Volume37.39M
Avg. Volume329.49K
Avg. Weekly Volume476.25K
Avg. Monthly Volume418.78K
Avg. Quarterly Volume347.19K

Atea Pharmaceuticals Inc. (NYSE: AVIR) stock closed at 39.76 per share at the end of the most recent trading day (a -2.33% change compared to the prior day closing price) with a volume of 391.78K shares and market capitalization of 3.29B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 19 people. Atea Pharmaceuticals Inc. CEO is Jean-Pierre Sommadossi.

The one-year performance of Atea Pharmaceuticals Inc. stock is 31.77%, while year-to-date (YTD) performance is -4.83%. AVIR stock has a five-year performance of %. Its 52-week range is between 24.15 and 94.17, which gives AVIR stock a 52-week price range ratio of 22.29%

Atea Pharmaceuticals Inc. currently has a PE ratio of -88.10, a price-to-book (PB) ratio of 6.79, a price-to-sale (PS) ratio of 75.71, a price to cashflow ratio of 3.30, a PEG ratio of 2.32, a ROA of -2.47%, a ROC of -20.04% and a ROE of -4.39%. The company’s profit margin is -22.51%, its EBITDA margin is 42.50%, and its revenue ttm is $48.63 Million , which makes it $0.59 revenue per share.

Of the last four earnings reports from Atea Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.25 for the next earnings report. Atea Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Atea Pharmaceuticals Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Atea Pharmaceuticals Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Atea Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Atea Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.96, ATR14 : 5.23, CCI20 : -148.38, Chaikin Money Flow : -0.17, MACD : -8.21, Money Flow Index : 27.36, ROC : -32.70, RSI : 25.42, STOCH (14,3) : 7.79, STOCH RSI : 0.00, UO : 33.94, Williams %R : -92.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Atea Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.

CEO: Jean-Pierre Sommadossi

Telephone: +1 857 284-8891

Address: 125 Summer Street, Boston 02110, MA, US

Number of employees: 19

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

62%38%

Bearish Bullish

82%18%

Bearish Bullish

62%38%

News

Stocktwits